ABSTRACT

This chapter presents a trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interaction of Pipotiazine. Pipotiazine, a long-acting depot phenothiazine formulation, has been found to be of particular benefit for patients who have chronic, non-agitated schizophrenia and require long-term maintenance pharmacotherapy. If pipotiazine pharmacotherapy is required, advise patients of potential benefits and possible risks to themselves and the embryo, fetus, or neonate. Collaboration with the patient’s obstetrician is indicated. Pipotiazine, a long-acting depot phenothiazine formulation is indicated for patients who are stabilized on short-acting antipsychotic pharmacotherapy and who may benefit from long-acting antipsychotic pharmacotherapy. A single intramuscular injection of pipotiazine generally manages the signs and symptoms of schizophrenia for three to six weeks. Most patients can be satisfactorily dosed once monthly.